Miranda M Fidler1, Raoul C Reulen1, David L Winter1, Rodrigue S Allodji1, Francesca Bagnasco1, Edit Bárdi1, Andrea Bautz1, Chloe J Bright1, Julianne Byrne1, Elizabeth A M Feijen1, Stanislaw Garwicz1, Desiree Grabow1, Thorgerdur Gudmundsdottir1, Joyeeta Guha1, Nadia Haddy1, Momcilo Jankovic1, Peter Kaatsch1, Melanie Kaiser1, Rahel Kuonen1, Helena Linge1, Milena Maule1, Franco Merletti1, Hilde Øfstaas1, Cecile M Ronckers1, Roderick Skinner1, Jop Teepen1, Monica Terenziani1, Giao Vu-Bezin1, Finn Wesenberg1, Thomas Wiebe1, Zsuzsanna Jakab1, Riccardo Haupt1, Päivi Lähteenmäki1, Lorna Zadravec Zaletel1, Claudia E Kuehni1, Jeanette F Winther1, Florent de Vathaire1, Leontien C Kremer1, Lars Hjorth1, Michael M Hawkins1. 1. Centre for Childhood Cancer Survivor Studies, Institute of Applied Health Research, University of Birmingham, Birmingham, UK; Section of Cancer Surveillance, International Agency for Research on Cancer, Lyon, France; Cancer and Radiation Team, U1018 INSERM, Villejuif, France; Epidemiology and Biostatistics Section, Gaslini Children Hospital, Genova, Italy; 2nd Department of Pediatrics, Semmelweis University, Budapest, Hungary; Kepler Universitätsklinikum, Linz, Austria; Survivorship Unit, Danish Cancer Society Research Center, Copenhagen, Denmark; Boyne Research Institute, Drogheda, Ireland; Department of Pediatric Oncology, Emma Children's Hospital/Academic Medical Center, Amsterdam, the Netherlands; Department of Pediatrics, Skane University Hospital, Lund University, Lund, Sweden; German Childhood Cancer Registry, Institute of Medical Biostatistics, Epidemiology and Informatics, University Medical Center, Mainz, Germany; Children's Hospital, Landspitali University Hospital, Reykjavik, Iceland; Pediatric Hematology Unit, San Gerardo Hospital, Monza, Italy; Swiss Childhood Cancer Registry, Institute of Social and Preventive Medicine, University of Bern, Bern, Switzerland; Childhood Cancer Registry of Piedmont, Cancer Epidemiology Unit, Department of Medical Sciences, University of Turin and AOU Città della Salute e della Scienza di Torino, Torino, Italy; Norwegian National Advisory Unit on Solid Tumors in Children; Great North Children's Hospital, Newcastle upon Tyne Hospitals NHS Foundation Trust, and Northern Institute of Cancer Research, Newcastle University, Newcastle upon Tyne, UK; Pediatric Oncology Unit, Fondazione IRCCS Istituto Nazionale dei Tumori, Milano, Italy; Norwegian Cancer Registry and Department of Pediatric Medicine, Oslo University Hospital, Oslo, Norway; Faculty of Medicine, Institute of Clinical Medicine, University of Oslo, Norway; Hungarian Childhood Cancer Registry, 2nd Department of Pediatrics, Semmelweis University, Budapest, Hungary; Department of Pediatrics and Adolescent Medicine, Turku University and Turku University Hospital, Turku, Finland; Institute of Oncology, Ljubljana, Slovenia; Department of Pediatrics, University Children's Hospital of Bern, University of Bern, Bern, Switzerland.
Abstract
Introduction: We investigate the risks of subsequent primary bone cancers after childhood and adolescent cancer in 12 European countries. For the first time, we satisfactorily address the risks beyond 40 years from diagnosis and beyond 40 years of age among all survivors. Methods: This largest-ever assembled cohort comprises 69 460 five-year survivors of cancer diagnosed before age 20 years. Standardized incidence ratios, absolute excess risks, and multivariable-adjusted relative risks and relative excess risks were calculated. All statistical tests were two-sided. Results: Overall, survivors were 21.65 times (95% confidence interval = 18.97 to 24.60 times) more likely to be diagnosed with a subsequent primary bone cancer than expected from the general population. The greatest excess numbers of bone cancers were observed after retinoblastoma, bone sarcoma, and soft tissue sarcoma. The excess number of bone cancers declined linearly with both years since diagnosis and attained age (all P < .05). Beyond 40 years from diagnosis and age 40 years, there were at most 0.45 excess bone cancers among all survivors per 10 000 person-years at risk; beyond 30 years from diagnosis and age 30 years, there were at most 5.02 excess bone cancers after each of retinoblastoma, bone sarcoma, and soft tissue sarcoma, per 10 000 person-years at risk. Conclusions: For all survivors combined and the cancer groups with the greatest excess number of bone cancers, the excess numbers observed declined with both age and years from diagnosis. These results provide novel, reliable, and unbiased information about risks and risk factors among long-term survivors of childhood and adolescent cancer.
Introduction: We investigate the risks of subsequent primary bone cancers after childhood and adolescent cancer in 12 European countries. For the first time, we satisfactorily address the risks beyond 40 years from diagnosis and beyond 40 years of age among all survivors. Methods: This largest-ever assembled cohort comprises 69 460 five-year survivors of cancer diagnosed before age 20 years. Standardized incidence ratios, absolute excess risks, and multivariable-adjusted relative risks and relative excess risks were calculated. All statistical tests were two-sided. Results: Overall, survivors were 21.65 times (95% confidence interval = 18.97 to 24.60 times) more likely to be diagnosed with a subsequent primary bone cancer than expected from the general population. The greatest excess numbers of bone cancers were observed after retinoblastoma, bone sarcoma, and soft tissue sarcoma. The excess number of bone cancers declined linearly with both years since diagnosis and attained age (all P < .05). Beyond 40 years from diagnosis and age 40 years, there were at most 0.45 excess bone cancers among all survivors per 10 000 person-years at risk; beyond 30 years from diagnosis and age 30 years, there were at most 5.02 excess bone cancers after each of retinoblastoma, bone sarcoma, and soft tissue sarcoma, per 10 000 person-years at risk. Conclusions: For all survivors combined and the cancer groups with the greatest excess number of bone cancers, the excess numbers observed declined with both age and years from diagnosis. These results provide novel, reliable, and unbiased information about risks and risk factors among long-term survivors of childhood and adolescent cancer.
Authors: Emily S Tonorezos; Danielle Novetsky Friedman; Dana Barnea; Machteld I Bosscha; Guillermo Chantada; Charlotte J Dommering; Pim de Graaf; Ira J Dunkel; Armida W M Fabius; Jasmine H Francis; Mary-Louise C Greer; Ruth A Kleinerman; Wijnanda A Kors; Suzanne Laughlin; Annette C Moll; Lindsay M Morton; Petra Temming; Margaret A Tucker; Flora E van Leeuwen; Michael F Walsh; Kevin C Oeffinger; David H Abramson Journal: Ophthalmology Date: 2020-05-15 Impact factor: 12.079
Authors: Smita C Banerjee; Elaine Pottenger; Mary Petriccione; Joanne F Chou; Jennifer S Ford; Charles A Sklar; Leslie L Robison; Ruth A Kleinerman; Kevin C Oeffinger; Jasmine H Francis; David H Abramson; Ira J Dunkel; Danielle Novetsky Friedman Journal: Palliat Support Care Date: 2020-06
Authors: Sara J Schonfeld; Diana M Merino; Rochelle E Curtis; Amy Berrington de González; Megan M Herr; Ruth A Kleinerman; Sharon A Savage; Margaret A Tucker; Lindsay M Morton Journal: JNCI Cancer Spectr Date: 2019-06-20
Authors: Lucie M Turcotte; Joseph P Neglia; Raoul C Reulen; Cecile M Ronckers; Flora E van Leeuwen; Lindsay M Morton; David C Hodgson; Yutaka Yasui; Kevin C Oeffinger; Tara O Henderson Journal: J Clin Oncol Date: 2018-06-06 Impact factor: 44.544
Authors: Desiree Grabow; Melanie Kaiser; Lars Hjorth; Julianne Byrne; Daniela Alessi; Rodrigue S Allodji; Francesca Bagnasco; Edit Bárdi; Andrea Bautz; Chloe J Bright; Florent de Vathaire; Elizabeth A M Feijen; Stanislaw Garwicz; Oskar Hagberg; Riccardo Haupt; Mike M Hawkins; Zsuzsanna Jakab; Leontien C M Kremer; Claudia E Kuehni; Rahel Kuonen; Päivi Maria Lähteenmäki; Raoul C Reulen; Cécile M Ronckers; Carlotta Sacerdote; Giao Vu-Bezin; Finn Wesenberg; Thomas Wiebe; David L Winter; Jeanette Falck Winther; Lorna Zadravec Zaletel; Peter Kaatsch Journal: Eur J Epidemiol Date: 2018-03-02 Impact factor: 8.082
Authors: Elisa Mazzoni; Ilaria Bononi; Maria S Benassi; Piero Picci; Elena Torreggiani; Marika Rossini; Andrea Simioli; Maria V Casali; Paola Rizzo; Mauro Tognon; Fernanda Martini Journal: Front Cell Dev Biol Date: 2018-06-22